Citi analyst Samantha Semenkow initiated coverage of Prime Medicine with a Neutral rating and $10 price target. Prime Medicine is an early-staged biotech focused on developing therapeutics using prime editing, the analyst tells investors in a research note. The firm believes prime editing could be transformative in treating a broad range of difficult diseases, but usays the clinical development path for Prime’s 18 pipeline programs “remains unclear.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRME:
- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine price target lowered to $18 from $19 at Morgan Stanley
- Prime Medicine files $500M mixed securities shelf
- Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Prime Medicine reports Q3 EPS (55c), consensus (46c)